121 results about "Vitreous humour" patented technology

An intraocular light probe has a mask or shield affixed at its distal end thereof which forms a directed light beam for intraocular illumination of target tissues or intraocular application of therapeutic light. The mask or shield serves to more fully focus, intensify and direct the beam toward the target tissues. The mask or shield also helps direct light away from other tissues and away from the eyes of the surgeon. This lessens unwanted glare. By placing a light probe beneath a surgical instrument such as a phacoemulsifier or vitrector, laser, cutting instrument (e.g., scissors or knife), forceps or probe/manipulator, whether as part of or separate from an infusion sleeve, a mask or shield effect is created. This has the same benefits of directing the beam toward target tissues, away from other tissues and away from the eyes of the surgeon. The mask or shield is opaque or semi-opaque and made of a soft, semi-rigid or rigid material. The shield can be rigid enough to serve as the shaft of an instrument with a probe or manipulator at its distal tip. It may also be reflective on the side adjacent to the fiber bundle to help direct, magnify, and intensify the beam of light. The shape of the shield can be flat, curved or circular with an opening along one side. The mask/shield can be removed from the fiberoptic light for sterilization. The device of the invention is preferably introduced into the eye via the primary or side-port incision to provide intraocular cross-lighting of tissues during surgical procedures such as cataract surgery, corneal surgery, vitrectomy, intraocular lens implantation, refractive surgery, glaucoma surgery and vitreo/retinal surgery.

A laser instrument for therapy on the human eye, designed for surgery of the cornea, the sclera, the vitreous body or the crystalline lens, especially suitable for use in immediate succession with other instruments for eye diagnosis or eye therapy, in such a way that during the alternating use of the various instruments, the eye or at least the patient preferably remains in a predetermined position and alignment within one and the same treatment area.

Disclosed is an optical coherence biological measurer. Parameters including corneal thicknesses, anterior chamber depths, lens thicknesses and visual axis lengths of eyes are obtained in once measurement by the aid of optical coherence measurement technology. The optical coherence biological measurer comprises a short coherence interferometry system detecting by the aid of balance, a retina splitimage focusing system, a visual axis aligning system with double fixation lamps, an optical length variable system, an eye positioning system and an auxiliary focusing system. The eye positioning system images the surface of a cornea and positions an eye, a system optical axis matches with an visual axis of the eye by the aid of the visual axis aligning system with the double fixation lamps, detecting light is respectively focused on a retina, a vitreous body and the cornea by an optical length and focus linkage device, simultaneously, optical length compensation of reference light is realized, the optical length variable system is used for realizing scanning measurement for return light signals of the retina, the vitreous body and the cornea, and the visual axis length, the vitreous bodythickness, the anterior chamber depth and the corneal thickness are calculated by the aid of output signals of a balance photoelectric detector.

An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.

A method is disclosed for creating a separation of posterior cortical vitreous from the retina of the eye. The method includes the step of introducing plasmin into the vitreous humor of the eye. The plasmin may be introduced either by injection or through a sustained release device. Optionally, other enzymes, polysaccharides, and/or glycoproteins are intermixed with the plasmin.

A process for inhibiting vascular proliferation separately introduces components into the eye to generate plasmin in the eye in amounts to induce complete posterior vitreous detachment where the vitreoretinal interface is devoid of cortical vitreous remnants. The process administers a combination of lysine-plasminogen, at least one recombinant plasminogen activator selected from the group consisting of urokinase, streptokinase, tissue plasminogen activator, chondroitinase, pro-urokinase, retavase, metaloproteinase, and thermolysin and a gaseous adjuvant to form a cavity in the vitreous. The composition is introduced into the vitreous in an amount effective to induce crosslinking of the vitreous and to induce substantially complete posterior vitreous detachment from the retina without causing inflammation of the retina. The gaseous adjuvant material is introduced into the vitreous simultaneously with or after the lysine-plasminogen and recombinant plasminogen activator such as recombinant urokinase to compress the vitreous against the retina while the composition induces the complete posterior vitreous detachment.

Compositions and methods useful for at least assisting in visualizing vitreous bodies of eyes of humans or animals are provided. Such compositions include a contrast component and a carrier component and are substantially free of any therapeutic agent effective to have pharmacological activity in an eye in which the composition is placed. Methods of using such compositions as visualization devices are also provided.

The invention discloses a black micro-crystalline glass plate made of gold ore tailings, which is prepared from the following raw materials in part by mass: gold ore tailings 60-90, quartz sand 8-20, calcite 0.5-2, nepheline 1-2, sodium carbonate 2-5, borax 1-2, barium carbonate 1-8, sodium nitrate 2-6 and cobalt oxide 0.1-0.5. A manufacturing method comprises: crushing and screening the gold ore tailings, the quartz sand, the calcite and the nepheline; removing cyanides from the gold ore tailings by an iron exchange method; weighing the raw materials in proportion and preparing a mixed material; melting the mixed material at 1,250 to 1,350 DEG C to form vitreous humour; allowing molten vitreous humour directly to flow into water to be quenched by water into glass grains; flatly spreading the glass grains in a refractory mould for crystallization; and grinding and cutting an obtained black crystalline glass sample. Compared with the traditional black crystalline glass, the product has more higher quality, and has the advantages of high Mohs' hardness, high bending strength, high chemical stability and pure color.

Described is a highly safe means to improve visibility of transparent tissues of the eye, i.e., the vitreous body, the lens or the cornea, in a surgical operation on them. The means comprises fine particles of a macromolecular compound, in particular, those one gram of which cannot be dissolved in less than 30 mL of water within 30 minutes at 20° C., and whose average particle size is 0.01-500 μm, and which, among others, is a biodegradable macromolecular compound and/or a water soluble macromolecular compound.

The invention belongs to the field of medical apparatuses and instruments and particularly discloses a human eye test model for evaluating the three-dimensional imaging performance of OCT equipment of the ophthalmology department and a use method of the human eye test model. A simulated human eye is provided with key parts of imaging of the ophthalmology department, wherein the key parts include the cornea (2), the atria (3), the crystalline lens (5), the vitreous body (7) and the retina (8). An OCT resolution test pattern (9) and a view marking ring (10) are designed and distributed on the surface of the retina. The OCT resolution test pattern (9) includes two parts. One part of patterns are used for evaluating the OCT transverse resolution, all sets of patterns are the same in height, each set of pattern is composed of three short lines in the horizontal direction and three short lines in the vertical direction on the two-dimensional plane, and the lengths of the short lines gradually decrease; the other part of patterns are used for evaluating the OCT axial resolution, each set of pattern is a square on the two-dimensional plane, the length and the width of each square are the same, but the heights of the squares gradually decrease. The human eye test model is designed and manufactured according to the imaging principle of the OCT equipment, and the three-dimensional resolution performance of the OCT equipment can be evaluated by carrying out measurement and imaging on the simulated human eye.

A device and a method for the femtosecond laser surgery of tissue, especially in the vitreous humor of the eye. The device of includes an ultrashort pulse laser with pulse widths in the range of approximately 10 fs-1 ps, especially approximately 300 fs, pulse energies in the range of approximately 5 nJ-5μJ, especially approximately 1-2 μJ and pulse repetition rates of approximately 10 kHz-10 MHz, especially 500 kHz. The laser system is coupled to a scanner system which allows the spatial variation of the focus in three dimensions (x, y and z). In addition to the therapeutic laser/scanner optical system the device includes a navigation system.

The invention discloses a glass wool for a dry vacuum insulated panel core material and a production method thereof. The production method comprises the following steps of mixing the following components in parts by mass to form a mixture: 10.0-40.0 parts of quartz powder, 10.0-12.5 parts of feldspar, 9.0-11.0 parts of sodium borate, 1.5-3.5 parts of calcspar, 2.5-7.0 parts of dolomite, 7.0-15.0 parts of sodium carbonate and 15.0-60.0 parts of plate glass; adding the mixture into a melting tank of a kiln to melt and prepare vitreous humour; putting the vitreous humour into a bushing well and a centrifugal plate, and conveying to a centrifugal machine to spin and prepare the glass wool. The glass wool disclosed by the invention can be directly prepared into the dry vacuum insulated panel core material. Compared with the insulated panel core material produced by a wet process, the glass wool is short in production flow; and wet pulp is prepared without adding water or baking. Therefore, the production efficiency is improved; the energy source is greatly saved; the price of the insulated panel is reduced, and strong popularization and use of the market are facilitated.

The invention discloses an application of in-situ crosslinking hydrogel in preparing artificial vitreous bodies, which is characterized in that the in-situ crosslinking hydrogel is prepared by in-situ crosslinking after mixing a four-arm-end mercapto polyethylene glycol solution shown in the formula (I) and a polymer solution shown in the formula (II); wherein m in the formula (I) is an integer larger than 1, and n in the formula (II) is an integer larger than 1; and the two solutions are filled in eyes without vitreous bodies after mixing and can effectively form gel. A cell experiment and an animal in vivo experiment prove that the in-situ crosslinking hydrogel does not cause obvious inflammatory reaction and intraocular organ toxic reaction and can be used as the artificial vitreous bodies.

The invention relates to a plastically deformable implant for inserting into bodily orifices of the human or animal body. Implants of this type are used, for example, in ophthalmology, in particular, as vitreous body or lens replacements and in dentistry, for example, for filling extraction cavities in jaw-bones. Known implants, however, are not suitable for long-term use. The invention aims to provide a deformable plastic implant which also has a long-term application. This is achieved by the fact that the implant consists of a gel which is not sealed, containing fluorocarbon and which is directly introduced into the natural, or artificially created bodily orifice.

The present invention relates to a high-molecular film bag artificial vitreous body capable of regulating intraocular pressure and its making method. It includes bag, drainage-tube and ejection handle. Said bag is suitable to form and volume of human eye vitreous body cavity, the drainage-tube is connected on the upper portion of the bag, said drainage-tube is equipped with drainage valve, the bag and the drainage tube are hid in the ejection handle, and the bag is held by head of the ejection handle.

A capsular bag for artificial vitreous body is made up of one selected from the group comprising polysiloxane, polyurethane, styrene triblock copolymer thermoplastic elastomers, hydroxyethyl methacrylate, polyvinyl alcohol, poly(lactide-co-glycolide) and hyaluronic acid ester. A method for manufacturing the capsular bag for artificial vitreous body is performed with dip-molding, effectively improving the smoothness of inner surface of the capsule, comprising: an eye die is dipped into gel solution until the surface adsorbs gel and then lifted, repeating the step 3-6 times; the dipped eye is hardened into shape; a shaped spherical outer capsule is peeled out of the eye die. The capsular bag for artificial vitreous body had high biocompatibility and excellent flexibility.

A supporting frame of vitreous body cavity for treating retinopathy is a Rugby football-shaped single-layer netted structure with a front opening (1.0-2.2 mm in diameter) and a rear yellow spot hole (0.5-1.5 mm in diameter). Said netted structure is made of Ni-Ti marmem. Its preparing method is also disclosed.

The invention discloses a stitch-free silicon rubber corneal arcus for use in a vitreous body resection operation using a needle with casing pipes, which consists of a medical silicon rubber ring, wherein the surface between the upper and lower two ends of the ring have a spherical shape having a curvature similar to that of eye balls; the periphery of the bottom surface of the ring is provided with first sectorial thin claw, second sectorial thin claw and third sectorial thin claw which have the same structure at the positions corresponding to three casting pipes respectively; the inside diameter a of the ring is more than or equal to 10 millimeters and less than or equal to 12 millimeters, the thickness b is more than or equal to 1 millimeter and less than or equal to 2 millimeters, and the height c is more than or equal to 1 millimeter and less than or equal to 3 millimeters; the length e of the sectorial thin claws is more than or equal to 3 millimeters and less than or equal to 8 millimeters, the thickness f is more than or equal to 0.1 millimeter and less than or equal to 1.5 millimeters and the radian g of the sectors is more than or equal to 20 DEG and less than or equal to 90 DEG; and the coplanar curvature d of the bottom surface of the ring and the first, second and third sectorial thin claws ranges from 10 millimeters to 14 millimeters. The stitch-free silicon rubber corneal arcus has the advantages of simple structure, convenient operation, stable supporting effect and suitability for various vitreous body resection operation systems using the needle with casing pipes.

Methods and devices for implanting an intra-ocular pressure sensor within an eye of a patient are provided herein. Methods include penetrating a conjunctiva and sclera with a distal tip of a fluid-filled syringe and positioning the pressure sensor within a vitreous body of the eye by injecting the sensor device through the distal tip. The sensor device may be stabilized by one or more anchoring members engaged with the sclera so that the pressure sensor of the sensor device remains within the vitreous body. Methods further include advancing a sensor device having a distal penetrating tip through at least a portion of the sclera to position the sensor within the vitreous body and extracting of the sensor devices described herein by proximally retracting the sensor device using an extraction feature of the sensor device.

The present invention relates to a colored perfusion liquid exclusively for ophthalmic surgery. The colored perfusion liquid exclusively for ophthalmic surgery of the present invention includes conventional ophthalmic balanced salt solution and is characterized in that the present invention further contains 0.001 to 0.1mg/ml fluorescein sodium. The present invention firstly proposes the intraocular colored perfusion liquid and a concept of colored surgery, the present invention has the advantages that: the present invention can be filled in the anterior chamber, vitreous body, lens capsular bag and other lacunas, and can form the contrast with the intraocular transparent and semi-permeable membrane tissues, such as, cornea, lens capsule membrane, lens, vitreous body, retina and so on, therefore, the operator can identify such structures easily and the tissues which are difficult to identify become visible, therefore, the surgery becomes easy, the operation is accurate, the time is shorten, the retina, lens capsule membrane and other main structures are protected, the surgical complications are reduced, and better surgical effects are achieved accordingly. In addition, the present invention changes and overcomes the problems that the past localized staining method is time-consuming and needs to rinse, the surgical process is complicated, the operation is fairly troublesome, and the method can not carry out the differential display of the around tissues, that is the scope is too small etc.

A thimerosal-free hyaluronidase preparation wherein the preferred hyaluronidase enzyme is devoid of molecular weight fractions below 40,000 MW, between 60-70,000 MW and above 100,000 MW. Also disclosed is a method for accelerating the clearance of hemorrhagic blood from the vitreous humor of the eye, said method comprising the step of contacting at least one hemorrhage-clearing enzyme (e.g., a β-glucuronidase, matrix metalloproteinase, chondroitinase, chondroitin sulfatase or protein kinase) with the vitreous humor in an amount which is effective to cause accelerated clearance of blood therefrom.

The invention discloses an implantable intraocular quantitative medicine injection pump which comprises a medicine guiding pipe and a medicine adding bag, wherein a medicine inlet and a medicine outlet are arranged on the medicine adding bag, and one end of the medicine guiding pipe is communicated with the medicine outlet. While in use, the medicine adding bag is filled with medicine liquid and is punctured at the cornea segment, the medicine guiding pipe is inserted, the medicine adding bag is extruded, and the medicine liquid flows into the vitreous body through the medicine guiding pipe. The capacity of the medicine adding bag can be designed into a quantity required for single medication, an operator does not require repeating measuring medicine quantity during each medication, and the working efficiency is increased. The device can quantitatively medicate the eye posterior segment for multiple times without intraocular operation, is safe for implantation and easy for taking out, can reduce intraocular infection risk, can realize long-term sustainable medication to form effective medicine concentration and can enhance the local curative effects of the medicine in the eyes. The purpose of treating a series of intractable eye diseases requiring overall or local frequent medication is achieved, and the invention has great economical and social benefits and is very applicable to clinic application.

Disclosed herein are systems and methods for easy and rapid detection of ocular analytes in vitreous humor or aqueous humor. Specifically, exemplified are systems having a sample acquisition device that is in line with an analyte detection device. The system embodiments allow for the easy procurement and testing of samples. In a typical embodiment, the analyte detection assay device includes a housing that has a reaction chamber that is in fluid communication with a sample conduit and which contains reagents that specifically interact with the analyte. The reaction chamber is in fluid communication with a shunt that is in fluid communication with the sample conduit. The sample conduit has a sample conduit valve that is positioned distally to the shunt.

The invention discloses an OCT chromatography longitudinal scanning device for biological tissue measurement, which comprises a longitudinal scanning device and a phase modulation device, wherein the longitudinal scanning device comprises a wedge mirror group consisting of two wedge mirrors and a precision electrical control translation table; the two wedge mirrors have the same structure; one wedge mirror is fixed on the fixed end of the precision electrical control translation table, the other wedge mirror is fixed on the movable end of the precision electrical control translation table, and oblique edges between the two wedge mirrors are placed in parallel; the phase modulation device is arranged between a reference arm lens and an optical fiber coupler and comprises two semi-cylindrical vitreous bodies, a piezoelectric ceramic micro positioner and a single mode optical fiber; and the two semi-cylindrical vitreous bodies are connected through the piezoelectric ceramic micro positioner to form a piezoelectric ceramic post, and the outside of the piezoelectric ceramic post is wound with optical fibers and is sealed by glue. The device has the characteristics of simple control, good stability, and so on; and the wedge mirror group is adopted and the phase modulation device is added to the reference arm so as to reduce the amount of movement and measurement errors and improve the accuracy of measurement.